vs
Side-by-side financial comparison of Royalty Pharma plc (RPRX) and SCANSOURCE, INC. (SCSC). Click either name above to swap in a different company.
SCANSOURCE, INC. is the larger business by last-quarter revenue ($766.5M vs $622.0M, roughly 1.2× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 2.2%, a 32.3% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 2.5%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 0.9%).
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
ScanSource, Inc. is a leading global specialty technology distributor offering a broad portfolio of solutions including point-of-sale systems, barcode scanning tools, cybersecurity products, cloud services and communication solutions. It primarily serves value-added resellers, managed service providers and enterprise clients across North America, Latin America and Europe, covering retail, healthcare, industrial and public sector core segments.
RPRX vs SCSC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $622.0M | $766.5M |
| Net Profit | $214.2M | $16.5M |
| Gross Margin | — | 13.4% |
| Operating Margin | 62.4% | 2.3% |
| Net Margin | 34.4% | 2.2% |
| Revenue YoY | 4.8% | 2.5% |
| Net Profit YoY | 2.9% | -3.3% |
| EPS (diluted) | $0.49 | $0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $622.0M | $766.5M | ||
| Q3 25 | $609.3M | $739.6M | ||
| Q2 25 | $578.7M | $812.9M | ||
| Q1 25 | $568.2M | $704.8M | ||
| Q4 24 | $593.6M | $747.5M | ||
| Q3 24 | $564.7M | $775.6M | ||
| Q2 24 | $537.3M | $746.1M | ||
| Q1 24 | $568.0M | $752.6M |
| Q4 25 | $214.2M | $16.5M | ||
| Q3 25 | $288.2M | $19.9M | ||
| Q2 25 | $30.2M | $20.1M | ||
| Q1 25 | $238.3M | $17.4M | ||
| Q4 24 | $208.2M | $17.1M | ||
| Q3 24 | $544.0M | $17.0M | ||
| Q2 24 | $102.0M | $16.1M | ||
| Q1 24 | $4.8M | $12.8M |
| Q4 25 | — | 13.4% | ||
| Q3 25 | — | 14.5% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 14.2% | ||
| Q4 24 | — | 13.6% | ||
| Q3 24 | — | 13.1% | ||
| Q2 24 | — | 13.0% | ||
| Q1 24 | — | 12.6% |
| Q4 25 | 62.4% | 2.3% | ||
| Q3 25 | 70.1% | 3.5% | ||
| Q2 25 | 36.3% | 3.3% | ||
| Q1 25 | 94.0% | 3.2% | ||
| Q4 24 | 60.9% | 2.5% | ||
| Q3 24 | — | 2.3% | ||
| Q2 24 | 50.2% | 2.9% | ||
| Q1 24 | -13.0% | 2.3% |
| Q4 25 | 34.4% | 2.2% | ||
| Q3 25 | 47.3% | 2.7% | ||
| Q2 25 | 5.2% | 2.5% | ||
| Q1 25 | 41.9% | 2.5% | ||
| Q4 24 | 35.1% | 2.3% | ||
| Q3 24 | 96.3% | 2.2% | ||
| Q2 24 | 19.0% | 2.2% | ||
| Q1 24 | 0.8% | 1.7% |
| Q4 25 | $0.49 | $0.75 | ||
| Q3 25 | $0.67 | $0.89 | ||
| Q2 25 | $0.07 | $0.87 | ||
| Q1 25 | $0.55 | $0.74 | ||
| Q4 24 | $0.46 | $0.70 | ||
| Q3 24 | $1.21 | $0.69 | ||
| Q2 24 | $0.23 | $0.66 | ||
| Q1 24 | $0.01 | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $618.7M | $83.5M |
| Total DebtLower is stronger | $9.0B | — |
| Stockholders' EquityBook value | $9.7B | $910.9M |
| Total Assets | $19.6B | $1.7B |
| Debt / EquityLower = less leverage | 0.92× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $618.7M | $83.5M | ||
| Q3 25 | $938.9M | $124.9M | ||
| Q2 25 | $631.9M | $126.2M | ||
| Q1 25 | $1.1B | $146.3M | ||
| Q4 24 | $929.0M | $110.5M | ||
| Q3 24 | $950.1M | $145.0M | ||
| Q2 24 | $1.8B | $185.5M | ||
| Q1 24 | $843.0M | $159.1M |
| Q4 25 | $9.0B | — | ||
| Q3 25 | $8.9B | — | ||
| Q2 25 | $8.0B | — | ||
| Q1 25 | $7.6B | — | ||
| Q4 24 | $7.6B | — | ||
| Q3 24 | $7.6B | — | ||
| Q2 24 | $7.6B | — | ||
| Q1 24 | $6.1B | — |
| Q4 25 | $9.7B | $910.9M | ||
| Q3 25 | $9.6B | $914.0M | ||
| Q2 25 | $9.5B | $906.4M | ||
| Q1 25 | $9.8B | $901.7M | ||
| Q4 24 | $10.3B | $900.7M | ||
| Q3 24 | $10.3B | $920.9M | ||
| Q2 24 | $9.8B | $924.3M | ||
| Q1 24 | $9.9B | $944.1M |
| Q4 25 | $19.6B | $1.7B | ||
| Q3 25 | $19.3B | $1.7B | ||
| Q2 25 | $18.3B | $1.8B | ||
| Q1 25 | $17.6B | $1.7B | ||
| Q4 24 | $18.2B | $1.7B | ||
| Q3 24 | $18.0B | $1.8B | ||
| Q2 24 | $17.7B | $1.8B | ||
| Q1 24 | $16.1B | $1.8B |
| Q4 25 | 0.92× | — | ||
| Q3 25 | 0.93× | — | ||
| Q2 25 | 0.84× | — | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.74× | — | ||
| Q2 24 | 0.78× | — | ||
| Q1 24 | 0.62× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $827.1M | $30.8M |
| Free Cash FlowOCF − Capex | — | $28.9M |
| FCF MarginFCF / Revenue | — | 3.8% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | 3.86× | 1.87× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $827.1M | $30.8M | ||
| Q3 25 | $702.6M | $23.2M | ||
| Q2 25 | $364.0M | — | ||
| Q1 25 | $596.1M | $66.1M | ||
| Q4 24 | $742.5M | $-6.2M | ||
| Q3 24 | $703.6M | $44.8M | ||
| Q2 24 | $658.2M | — | ||
| Q1 24 | $664.6M | $160.2M |
| Q4 25 | — | $28.9M | ||
| Q3 25 | — | $20.8M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $64.6M | ||
| Q4 24 | — | $-8.2M | ||
| Q3 24 | — | $42.5M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $157.7M |
| Q4 25 | — | 3.8% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 9.2% | ||
| Q4 24 | — | -1.1% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 21.0% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | 3.86× | 1.87× | ||
| Q3 25 | 2.44× | 1.17× | ||
| Q2 25 | 12.06× | — | ||
| Q1 25 | 2.50× | 3.79× | ||
| Q4 24 | 3.57× | -0.36× | ||
| Q3 24 | 1.29× | 2.64× | ||
| Q2 24 | 6.45× | — | ||
| Q1 24 | 139.10× | 12.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
